GENE ONLINE|News &
Opinion
Blog

Aducanumab
EMA Rejects Marketing Authorization Application of Aduhelm
2021-12-20
AC Immune’s Stock Climbs Following Mixed Phase 2 Trial Results for Alzheimer’s Disease Drug
2021-09-01
Aftermath of Biogen’s Alzheimer’s Drug Approval Continues as Some Hospitals, Insurers Refuse Administration
2021-07-18
Biogen’s Controversial Alzheimer’s Drug Wins Historic FDA Approval
2021-06-07
Lilly’s Positive Data for Alzheimer’s Drug Bodes Well for Candidates Rooted in Amyloid Hypothesis
2021-03-14
Biogen’s Alzheimer’s Drug Turned Down by Independent Panel
2020-11-07
Biogen Stocks Rise Following FDA’s Inspiriting Comments on Alzheimer’s Drug, Aducanumab
2020-11-05
GeneOnline’s Top Ten Headlines of the Year
2019-12-30
LATEST
BIO 2023 Coming to Boston, with Over 60 Taiwanese Organizations to Share their Achievements
2023-06-02
2023 ASGCT Annual Meeting: Showcase of Exciting New Research, with a Focus on Clinical Applications
2023-06-02
Pfizer’s RSV Vaccine Gets FDA Approval for Use in Older Adults
2023-05-31
Brazil’s Evolving ESG Landscape from the Amazon to Atlantic Forest
2023-05-31
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
Scroll to Top